CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 54 enrolled
Drug / intervention
Calcitrioldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02125279
NCT02125279Phase 4Completed

A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis

Galderma R&D·interventional·Posted Apr 29, 2014·Updated Feb 18, 2021

In Brief

A Phase 4 clinical trial evaluating Calcitriol for Psoriasis Vulgaris. Completed, enrolled 54 participants across 16 sites in 5 countries.

Detailed Summary

The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Germany, Italy, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 29, 2014
Enrollment StartMay 1, 2014
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 12.2 years ago

Interventions

Calcitrioldrug